(19)
(11) EP 2 301 908 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.09.2014 Bulletin 2014/36

(45) Mention of the grant of the patent:
25.06.2014 Bulletin 2014/26

(21) Application number: 10014318.9

(22) Date of filing: 08.05.2008
(51) International Patent Classification (IPC): 
C07C 37/055(2006.01)
C07C 271/44(2006.01)
A61P 25/20(2006.01)
 C07C 39/06(2006.01)
A61K 31/05(2006.01)
C07C 39/27(2006.01)

(54)

(-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect, treatment of nausea and vomiting and treatment of migraine

(-)-Stereoisomer von 2,6-di-sec-butylphenol und Analoga davon für die Förderung antiemetische Wirkung und Behandlung von Übelkeit und Erbrechen und Behandlung von Migräne

(-)- stéréoisomère de 2,6-di-sec-butylphenol et ses analogues pour la promotion effet antiémétique et le traitement des nausées et des vomissements et le traitement de la migraine

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 09.05.2007 US 928327 P
09.05.2007 US 928429 P
09.05.2007 US 928296 P

(43) Date of publication of application:
30.03.2011 Bulletin 2011/13

(60) Divisional application:
14173149.7

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08769338.8 / 2146946

(73) Proprietor: Sowood Healthcare LLC
Boston, MA 02116 (US)

(72) Inventor:
  • Jenkins, Thomas E.
    Half Moon Bay CA 94019 (US)

(74) Representative: Wytenburg, Wilhelmus Johannes et al
Mewburn Ellis LLP 33 Gutter Lane
London EC2V 8AS
London EC2V 8AS (GB)


(56) References cited: : 
US-A- 2 747 982
   
  • KRASOWSKI MATTHEW D ET AL: "General anesthetic potencies of a series of propofol analogs correlate with potency for potentiation of gamma-aminobutyric acid (GABA) current at the GABAA receptor but not with lipid solubility", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 297, no. 1, 1 April 2001 (2001-04-01) , pages 338-351, XP002396851, ISSN: 0022-3565
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).